Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 7/2018

26.03.2018 | Laboratory Investigation

Evaluating the Feasibility of Isolated Pancreatic Perfusion for Chemotherapy Using Computed Tomography: An Experimental Study in Pig Models

verfasst von: Satoru Murata, Shiro Onozawa, Daisuke Yasui, Tatsuo Ueda, Fumie Sugihara, Akira Shimizu, Kenichi Suzuki, Mitsuo Satake

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Percutaneous isolated pancreatic perfusion (PIPP) is performed along with interventional radiology techniques to obtain high drug concentration by occluding the arterial inlet and venous outlet of the pancreas. The experimental study aimed to evaluate the contrast distribution in PIPP under different flow rates with or without anterior mesenteric artery (AMA) occlusion.

Materials and Methods

This study was approved by a local animal experiment ethics committee. Nine pigs were divided into Groups 1, 2, and 3, by infusion rates of 12, 24, and 36 mL/min. Groups 4 and 5 (3 pigs each) and Group 6 (2 pigs) underwent PIPP at the same respective infusion rates with and without AMA occlusion. Computed tomography (CT) arteriography was performed during PIPP with nonionic contrast media. The enhanced volume was calculated by adding the enhanced area in each slice using 1.25-mm axial images. The percent enhanced volume to the whole pancreas (%eV) was used to simulate drug distribution; the result was compared among groups.

Results

Without AMA occlusion, a larger %eV was obtained with high infusion rates (P = 0.039). The median %eV in Groups 1, 2, and 3 were 57.7, 74.2, and 90.5%, respectively. With AMA occlusion, CT demonstrated duodenal enhancement at an infusion rate of 36 mL/min, and the median %eV in Groups 4, 5, and 6 were 92.8, 95.4, and 98.5%, respectively. A significantly larger %eV was obtained after AMA occlusion (P = 0.031).

Conclusion

A higher infusion rate or AMA occlusion increases the enhanced volume in PIPP in pig models.

Level of evidence

No level of evidence.
Literatur
2.
Zurück zum Zitat Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.CrossRefPubMed Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.CrossRefPubMed
3.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed
4.
Zurück zum Zitat Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progression? A meta-analysis of 20 phase 3 trials. Cancer. 2007;110:525–33.CrossRefPubMed Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progression? A meta-analysis of 20 phase 3 trials. Cancer. 2007;110:525–33.CrossRefPubMed
5.
Zurück zum Zitat Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–51.CrossRefPubMed Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–51.CrossRefPubMed
6.
Zurück zum Zitat Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group– directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.CrossRefPubMedPubMedCentral Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group– directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer. 2000;89:303–13.CrossRefPubMed Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer. 2000;89:303–13.CrossRefPubMed
8.
Zurück zum Zitat Takamori H, Kanemitsu K, Hirota M, Ikeda O, Tanaka H, Beppu T, Yamashita Y, Oya N, Baba H. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Ann Surg Oncol. 2011;18:1110–5.CrossRefPubMed Takamori H, Kanemitsu K, Hirota M, Ikeda O, Tanaka H, Beppu T, Yamashita Y, Oya N, Baba H. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Ann Surg Oncol. 2011;18:1110–5.CrossRefPubMed
9.
Zurück zum Zitat Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y. Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Interv Radiol. 2006;29:362–70.CrossRef Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y. Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Interv Radiol. 2006;29:362–70.CrossRef
10.
Zurück zum Zitat Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, Kichikawa K. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. Am J Roentgenol. 2007;189:421–8.CrossRef Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, Kichikawa K. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. Am J Roentgenol. 2007;189:421–8.CrossRef
11.
Zurück zum Zitat Tanaka T, Yamamoto K, Sho M, Nishiofuku H, Inoue M, Sueyoshi S, Anai H, Sakaguchi H, Nakajima Y, Kichikawa K. Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. J Vasc Interv Radiol. 2010;21:116–21.CrossRefPubMed Tanaka T, Yamamoto K, Sho M, Nishiofuku H, Inoue M, Sueyoshi S, Anai H, Sakaguchi H, Nakajima Y, Kichikawa K. Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. J Vasc Interv Radiol. 2010;21:116–21.CrossRefPubMed
12.
Zurück zum Zitat Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Yasui D, Kumita S, Shimizu A, Satake M. Minimizing systemic leakage of cisplatin during percutaneous isolated pancreas perfusion chemotherapy: a pilot study. Radiology. 2015;276:102–9.CrossRefPubMed Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Yasui D, Kumita S, Shimizu A, Satake M. Minimizing systemic leakage of cisplatin during percutaneous isolated pancreas perfusion chemotherapy: a pilot study. Radiology. 2015;276:102–9.CrossRefPubMed
13.
Zurück zum Zitat Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465–74.CrossRefPubMedPubMedCentral Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465–74.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008;19:1127–34.CrossRefPubMed van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008;19:1127–34.CrossRefPubMed
15.
Zurück zum Zitat Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008;15:1107–16.CrossRefPubMed Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008;15:1107–16.CrossRefPubMed
16.
Zurück zum Zitat Murata S, Onozawa S, Sugihara F, Sakamoto A, Ueda T, Yamaguchi H, Yasui D, Mine T, Kumita S. Feasibility and safety of negative-balance isolated pelvic perfusion in patients with pretreated recurrent or persistent uterine cervical cancer. Ann Surg Oncol. 2015;22(12):3981–9.CrossRefPubMed Murata S, Onozawa S, Sugihara F, Sakamoto A, Ueda T, Yamaguchi H, Yasui D, Mine T, Kumita S. Feasibility and safety of negative-balance isolated pelvic perfusion in patients with pretreated recurrent or persistent uterine cervical cancer. Ann Surg Oncol. 2015;22(12):3981–9.CrossRefPubMed
17.
Zurück zum Zitat Aigner KR, Gailhofer S. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer: a phase II study on 265 cases. Anticancer Res. 2005;25:4407–12.PubMed Aigner KR, Gailhofer S. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer: a phase II study on 265 cases. Anticancer Res. 2005;25:4407–12.PubMed
18.
Zurück zum Zitat Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol. 2008;31:71–8.CrossRefPubMed Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol. 2008;31:71–8.CrossRefPubMed
19.
Zurück zum Zitat Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S, Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol. 2009;20:239–43.CrossRefPubMed Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S, Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol. 2009;20:239–43.CrossRefPubMed
20.
Zurück zum Zitat Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Nishiofuku H, Kichikawa K. Catheter position for adequate intra-arterial chemotherapy for advanced pancreatic cancer: evaluation with CT during arterial injection of contrast material. J Vasc Interv Radiol. 2004;15:1089–97.CrossRefPubMed Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Nishiofuku H, Kichikawa K. Catheter position for adequate intra-arterial chemotherapy for advanced pancreatic cancer: evaluation with CT during arterial injection of contrast material. J Vasc Interv Radiol. 2004;15:1089–97.CrossRefPubMed
21.
Zurück zum Zitat Li ES, Mu JX, Ji SM, Li XM, Xu LB, Chai TC, Liu JX. Total splenic artery embolization for splenic artery aneurysms in patients with normal spleen. World J Gastroenterol. 2014;14:555–60.CrossRef Li ES, Mu JX, Ji SM, Li XM, Xu LB, Chai TC, Liu JX. Total splenic artery embolization for splenic artery aneurysms in patients with normal spleen. World J Gastroenterol. 2014;14:555–60.CrossRef
Metadaten
Titel
Evaluating the Feasibility of Isolated Pancreatic Perfusion for Chemotherapy Using Computed Tomography: An Experimental Study in Pig Models
verfasst von
Satoru Murata
Shiro Onozawa
Daisuke Yasui
Tatsuo Ueda
Fumie Sugihara
Akira Shimizu
Kenichi Suzuki
Mitsuo Satake
Publikationsdatum
26.03.2018
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 7/2018
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-018-1943-y

Weitere Artikel der Ausgabe 7/2018

CardioVascular and Interventional Radiology 7/2018 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.